Yupelet

Yupelet, the distinguished name for revefenacin, is a long–acting muscarinic antagonist (LAMA) specifically designed for the ongoing governance of chronic obstructive pulmonary disease (COPD). It stands as the premier and sole once–daily nebulized LAMA, offering an elegant solution for patients with COPD who require sustained bronchodilation therapy.

General Information

Generic Name: Revefenacin

Brand Name: Yupelet

Drug Class: Long–acting muscarinic contender(LAMA), also recognized as an anticholinergic.

Mechanism of Action:

It effectively inhibits muscarinic receptors, predominately the M3 receptors, within the smooth muscles of the airways, thereby alleviating bronchoconstriction and enhancing airflow.

Uses and attestation

Indication:

Designed for the prolongation treatment of chronic obstructive lungs disease (COPD), encompassing chronic bronchitis and emphysema.

Not Indicated For:

Immediate relief of bronchospasm or as a rescue therapy.

Dosage and Administration

Form and Strength:

Inhalation solution: 175 mcg/3 mL in unit–dose vials for nebulization.

Dosage:

Adults:175 mcg (one unit–dose vial) inhaled once daily via a standard jet nebulizer connected to an air compressor.Pediatrics:Not approved for use in pediatric patients.

Administration:

Use only with a nebulizer.Ensure proper cleaning of the nebulizer to prevent contamination or infection.

Pharmacokinetics

Onset of Action: Improvement in lung function is typically observed within hours of administration.Duration of Action: Approximately 24 hours.Metabolism: Primarily metabolized in the liver by enzymes including CYP2D6 and CYP3A4.Elimination: Mainly excreted in feces; minimal renal excretion.

Therapeutic Benefits

Once–Daily Dosing:Simplifies treatment regimens for patients with COPD.Nebulized Form:Ideal for patients who may have difficulty using handheld inhalers due to physical or cognitive limitations.Effective Bronchodilation:Provides sustained improvements in lung function and reduces the risk of exacerbations.

Side Effects

Common Side Effects:Cough.Dry mouth.Headache.Upper respiratory tract infections.Nasopharyngitis (sore throat or runny nose).Less Common Side Effects:Diarrhea.Dizziness.Back pain.Serious Side Effects:Paradoxical bronchospasm (worsening of symptoms).Allergic reactions (rash, swelling, difficulty breathing).Worsening of narrow–angle glaucoma.Urinary retention, especially in patients with prostatic hyperplasia or bladder obstruction.

Warnings and Precautions

Paradoxical Bronchospasm:Can occur; discontinue immediately and seek medical attention.Narrow–Angle Glaucoma:Use with caution; may worsen symptoms.Urinary Retention:Monitor in patients with urinary tract obstruction or enlarged prostate.Liver Impairment:Use cautiously in patients with severe liver disease as the drug is metabolized in the liver.

Contraindications

Hypersensitivity to revefenacin or any ingredients in Yupari.History of severe hypersensitivity reactions to other LAMAs.

Drug Interactions

Anticholinergics:Avoid concurrent use with other anticholinergic drugs to prevent additive side effects.CYP3A4 and CYP2D6 Inhibitors:Strong inhibitors (e.g., ketoconazole) may increase systemic exposure to the drug.Other Respiratory Medications:Safe to use alongside other COPD maintenance therapies like inhaled corticosteroids or beta-agonists.

Special Populations

Pregnancy:Category C: Use only if the potential benefit justifies the risk to the fetus.Breastfeeding:Unknown if excreted in breast milk; use with caution.Pediatrics:Not approved for use in children.Elderly:No specific dose adjustment needed; monitor closely for side effects.

Overdose

Symptoms:Exaggerated anticholinergic effects, including dry mouth, blurred vision, urinary retention, and difficulty breathing.Management:Discontinue the drug and provide symptomatic treatment.

Efficacy

Clinical studies have shown that Yupelri significantly improves lung function (FEV1) compared to placebo in COPD patients.Reduces symptoms and exacerbation frequency in patients with moderate to severe COPD.

Patient Counseling Points

Proper Usage:Emphasize the importance of using Yupelri daily, even when symptoms are not present.Demonstrate correct nebulizer use.Missed Doses:If a dose is missed, take it as soon as remembered but not more than once in 24 hours.Side Effect Awareness:Report symptoms of glaucoma, urinary retention, or severe allergic reactions immediately.Storage:Store unit-dose vials at room temperature in their protective packaging until use.

Global Availability

Yupelri is FDA-approved and available in the U.S. and other countries. Its unique nebulized formulation makes it particularly suited for certain patient populations.

Summary

Yupelri (revefenacin) is a once–daily nebulized LAMA that offers sustained bronchodilation for COPD patients. Its convenient dosing and effectiveness make it a valuable option for those requiring maintenance therapy, particularly individuals who struggle with handheld inhaler devices. Proper administration, adherence, and monitoring are essential to maximize its benefits and minimize potential risks.